Forte Biosciences Inc
FBRX9.877USD
+0.268+2.78%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
65.01MCap. mercado
PérdidaP/E TTM
Más Datos de Forte Biosciences Inc Compañía
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The Company is advancing its product candidate, FB-102, which is a proprietary molecule with potentially broad autoimmune applications, including in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA). The Company’s FB-102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and T cell subsets. It owns one United States patent for administering a combination of Gram-positive and Gram-negative bacteria along with metabolites for treatment of a wide variety of skin conditions. The Company’s subsidiaries include Forte Subsidiary, Inc., Forte Biosciences Emerald Limited, and Forte Biosciences Australia Pty Ltd.
Información de la empresa
Símbolo de cotizaciónFBRX
Nombre de la empresaForte Biosciences Inc
Fecha de salida a bolsaApr 13, 2017
Director ejecutivoDr. Paul A. Wagner, Ph.D.
Número de empleados14
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 13
Dirección- -
Ciudad- -
Bolsa de valoresNASDAQ Capital Market Consolidated
País- -
Código postal- -
Teléfono- -
Sitio Web- -
Símbolo de cotizaciónFBRX
Fecha de salida a bolsaApr 13, 2017
Director ejecutivoDr. Paul A. Wagner, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Paul A. Wagner, Ph.D.
Dr. Paul A. Wagner, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
80.94K
+1.44%
Mr. Antony A. Riley
Mr. Antony A. Riley
Chief Financial Officer
Chief Financial Officer
31.46K
+0.77%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
5.94K
--
Mr. Steven Kornfeld
Mr. Steven Kornfeld
Independent Director
Independent Director
3.96K
--
Dr. Barbara K. Finck, M.D.
Dr. Barbara K. Finck, M.D.
Director, Senior Medical Clinician
Director, Senior Medical Clinician
--
--
Dr. Stephen K. Doberstein, Ph.D.
Dr. Stephen K. Doberstein, Ph.D.
Independent Director
Independent Director
--
--
Mr. Richard G. (Rich) Vincent, CPA
Mr. Richard G. (Rich) Vincent, CPA
Independent Director
Independent Director
--
--
Dr. Scott C. Brun, M.D.
Dr. Scott C. Brun, M.D.
Independent Director
Independent Director
--
--
Mr. Shiv Kapoor
Mr. Shiv Kapoor
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Paul A. Wagner, Ph.D.
Dr. Paul A. Wagner, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
80.94K
+1.44%
Mr. Antony A. Riley
Mr. Antony A. Riley
Chief Financial Officer
Chief Financial Officer
31.46K
+0.77%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
5.94K
--
Mr. Steven Kornfeld
Mr. Steven Kornfeld
Independent Director
Independent Director
3.96K
--
Dr. Barbara K. Finck, M.D.
Dr. Barbara K. Finck, M.D.
Director, Senior Medical Clinician
Director, Senior Medical Clinician
--
--
Dr. Stephen K. Doberstein, Ph.D.
Dr. Stephen K. Doberstein, Ph.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 11 de jul
Actualizado: vie., 11 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Federated Hermes Global Investment Management Corp.
16.29%
Janus Henderson Investors
13.97%
Fred Alger Management, LLC
13.83%
Tybourne Capital Management (HK) Limited
11.95%
Ikarian Capital LLC
9.25%
Other
34.70%
Accionistas
Accionistas
Proporción
Federated Hermes Global Investment Management Corp.
16.29%
Janus Henderson Investors
13.97%
Fred Alger Management, LLC
13.83%
Tybourne Capital Management (HK) Limited
11.95%
Ikarian Capital LLC
9.25%
Other
34.70%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
52.18%
Hedge Fund
33.25%
Private Equity
9.01%
Corporation
7.45%
Individual Investor
1.91%
Investment Advisor
1.55%
Research Firm
0.05%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
79
7.00M
106.27%
+1.62M
2025Q1
80
5.91M
89.79%
+471.51K
2024Q4
82
5.78M
90.44%
+3.18M
2024Q3
72
948.15K
58.94%
-63.60K
2024Q2
79
972.89K
60.86%
-40.06K
2024Q1
108
982.74K
67.53%
-37.22K
2023Q4
121
973.92K
67.03%
-54.29K
2023Q3
139
1.01M
71.78%
+97.73K
2023Q2
175
455.32K
54.14%
-352.22K
2023Q1
185
468.85K
56.07%
-1.69M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Janus Henderson Investors
920.00K
13.97%
+229.26K
+33.19%
Mar 31, 2025
Fred Alger Management, LLC
910.61K
13.83%
-223.34K
-19.70%
Mar 31, 2025
Tybourne Capital Management (HK) Limited
619.98K
9.42%
--
--
Mar 31, 2025
Ikarian Capital LLC
609.23K
9.25%
--
--
Mar 31, 2025
BVF Partners L.P.
594.28K
9.03%
--
--
Mar 31, 2025
OrbiMed Advisors, LLC
593.09K
9.01%
-6.91K
-1.15%
Mar 31, 2025
Nemean Asset Management, LLC
432.28K
6.57%
+432.28K
--
Nov 22, 2024
Cable Car Capital LLC
219.60K
3.34%
--
--
Mar 31, 2025
Woodline Partners LP
204.82K
3.11%
+547.00
+0.27%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Micro-Cap ETF
0.02%
Fidelity Nasdaq Composite Index ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Alger 35 ETF
0%
iShares Micro-Cap ETF
Proporción0.02%
Fidelity Nasdaq Composite Index ETF
Proporción0%
iShares Core S&P Total U.S. Stock Market ETF
Proporción0%
Alger 35 ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Aug 22, 2024
Merger
25<1
Aug 22, 2024
Merger
25<1
Aug 22, 2024
Merger
25<1
Aug 22, 2024
Merger
25<1
Jun 15, 2020
Merger
15<1
Jun 15, 2020
Merger
15<1
Fecha
Tipo
Relación
Aug 22, 2024
Merger
25<1
Aug 22, 2024
Merger
25<1
Aug 22, 2024
Merger
25<1
Aug 22, 2024
Merger
25<1
Jun 15, 2020
Merger
15<1
Jun 15, 2020
Merger
15<1
Jun 15, 2020
Merger
15<1
Jun 15, 2020
Merger
15<1
